Compounds · Retatrutide

Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on

Compounds › Retatrutide retatrutide preprint randomised trial

Solved Closed

Solved by no.silva in post #3

Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.

Jump to the accepted answer →

am.wikstromTL2 Moderator17 Jul 2025#1

The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it.

Comparing STEP 4 (JAMA, 2021) with SURPASS-2 (N Engl J Med, 2021) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

56 likes 12mo

np_gilmoreTL3Nurse practitioner14 Aug 2025#2

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

15 likes 11mo

no.silvaTL2 Moderator Solution4 Sep 2025#3

Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.

6 likes 11mo

peak_purityTL3Analytical chemist22 Sep 2025#4

post #3 is right about the mechanism and I think understates the practical bit.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

1 like 10mo

r.zielinskiTL2 Moderator9 Oct 2025#5

am.wikstrom, post #1: The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 ( JAMA , 2021) with SURPASS-2 ( N Engl J Med , 2021) and finding the comparison harder than it looks. Different populations,… Go to post

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

0 likes in reply to #1 10mo

This topic was referenced in

Why retatrutide discussion here is more cautious than elsewhere — one year onCompounds › Retatrutide · 97 replies

This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+71	80	38k	11mo
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Compounds › Retatrutide effect size randomised trial TRIUMPH programme Solved Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med…		2	103	17mo
How to read a phase 2 result without treating it as a phase 3 result Compounds › Retatrutide randomised trial preprint effect size TRIUMPH programme The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…	+36	40	35k	7mo

Related topics — sharing the tags retatrutide, preprint, randomised trial

Topic	Participants	Replies	Views	Activity
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Pharmacology › Receptor biology tirzepatide retatrutide amylin analogues long read Under review Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+52	57	25k	just now
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Evidence › Journal club estimand randomised trial number needed to treat effect size Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…	+126	138	31k	17mo
The most common factual error about semaglutide on the internet Compounds › Semaglutide STEP programme randomised trial type 2 diabetes effect size On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…		2	49k	2y
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
Second pass at: Journal club: LEADER as the historical anchor Evidence › Journal club randomised trial journal club effect size estimand Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…	+75	81	2k	2y

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →